Zobrazeno 1 - 10
of 56
pro vyhledávání: '"ROBERT S. KAUFFMAN"'
Autor:
Bambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, Karen Eisenhauer, Holly Kimko, John J Alam, Robert S Kauffman, Varun Garg
Publikováno v:
PLoS Computational Biology, Vol 8, Iss 1, p e1002339 (2012)
We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/r
Externí odkaz:
https://doaj.org/article/1ebc60fb8b8d4ddcaf1eafea5ed2727d
Autor:
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann Tigges, Inge Dierynck, Joan Spanks, Jennifer Dorrian, Min Jiang, Bambang Adiwijaya, Anne Ghys, Maria Beumont, Robert S Kauffman, Nathalie Adda, Ira M Jacobson, Kenneth E Sherman, Stefan Zeuzem, Ann D Kwong, Gaston Picchio
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34372 (2012)
BackgroundIn patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic cha
Externí odkaz:
https://doaj.org/article/1dbcfc20320f40f0bb077dc356b2c9f4
Autor:
Akshay Vaishnaw, Peter L.J. Wijngaard, Amy Simon, Brian Bettencourt, Kevin Fitzgerald, Jay D. Horton, Chamikara Fernando, Jorg Taubel, Anna Borodovsky, Ashley Brooks, Valerie A. Clausen, Andrew Strahs, Robert S. Kauffman, David Kallend, Suellen White
Publikováno v:
New England Journal of Medicine. 376:41-51
BackgroundInclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin–kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::785b9837d364de10753887f8881d7c1a
https://doi.org/10.1056/nejmoa1609243
https://doi.org/10.1056/nejmoa1609243
Autor:
Hans W. Sollinger, Mark H. Deierhoi, Robert S. Kauffman, Arnold G. Diethelm, Folkert O. Belzer
Publikováno v:
Transplant International. 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05256b1546cc3669ec124cda43696f32
Autor:
Jim Witek, Christoph Sarrazin, Donghan Luo, Leif Bengtsson, I. Dierynck, N. Adda, Tara L. Kieffer, Robert S. Kauffman, Linda Gritz, Gaston Picchio, Douglas J. Bartels, Sandra De Meyer, Anne Ghys
Publikováno v:
Journal of Clinical Virology. 59:148-155
Background Telaprevir-based therapy is associated with rapid decline in HCV RNA, enabling the application of early futility rules. Objectives To familiarize physicians with this paradigm, a comprehensive analysis of the most frequent HCV viral load p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d63d0f095f686d4862f4e5d6daa35d
https://doi.org/10.1016/j.jcv.2013.12.011
https://doi.org/10.1016/j.jcv.2013.12.011
Publikováno v:
Antiviral Therapy. 17:1211-1221
Telaprevir is an inhibitor of the HCV NS3/4A protease. When used in combination with pegylated interferon and ribavirin, telaprevir has demonstrated a substantial increase in sustained virological response compared with pegylated interferon and ribav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df6dc0642abc836533482063d12b82b6
https://doi.org/10.3851/imp2356
https://doi.org/10.3851/imp2356
Publikováno v:
Nature Biotechnology. 29:993-1003
Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide. Substantial morbidity and mortality are associated with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0601a67c976763605666bc40f1d26
https://doi.org/10.1038/nbt.2020
https://doi.org/10.1038/nbt.2020
Autor:
Robert S. Kauffman, Eric Lawitz, Lindsay McNair, Nezam H. Afdhal, Gurudatt Chandorkar, Stuart C. Gordon, William M. Lee, Matthew W. Harding, Molly Aalyson, Herbert L. Bonkovsky, Vinod K. Rustgi, John Alam, John G. McHutchison, Leif Bengtsson, Shahin Gharakhanian, Fred Poordad
Publikováno v:
Hepatology. 50:1719-1726
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1a9b749b2ef4c941271f9fde2157fd
https://doi.org/10.1002/hep.23204
https://doi.org/10.1002/hep.23204
Publikováno v:
Arthritis & Rheumatism. 60:1232-1241
Objective To assess the efficacy and safety of VX-702, a p38 MAPK inhibitor, in patients with active, moderate-to-severe rheumatoid arthritis (RA). Methods Two 12-week, double-blind, placebo-controlled studies of VX-702 were conducted in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9edeb3e98df56605d59417a60d9f36
https://doi.org/10.1002/art.24485
https://doi.org/10.1002/art.24485
Autor:
Christophe, Hézode, Nicole, Forestier, Geoffrey, Dusheiko, Peter, Ferenci, Stanislas, Pol, Tobias, Goeser, Jean-Pierre, Bronowicki, Marc, Bourlière, Shahin, Gharakhanian, Leif, Bengtsson, Lindsay, McNair, Shelley, George, Tara, Kieffer, Ann, Kwong, Robert S, Kauffman, John, Alam, Jean-Michel, Pawlotsky, Stefan, Zeuzem, P, Ferenci
Publikováno v:
New England Journal of Medicine. 360:1839-1850
Background In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed7e71dd89258892ba129069932ffac
https://doi.org/10.1056/nejmoa0807650
https://doi.org/10.1056/nejmoa0807650